Zoo or Savannah? Choice of Training Ground for Evidence-Based Pharmacovigilance

Drug Safety

Volumn 37, Issue 9, 2014, Pages 655-659

  Norén, G Niklas ^a,b   Caster, Ola ^a,b   Juhlin, Kristina ^a   Lindquist, Marie ^a  

^a UPPSALA MONITORING CENTRE   (Sweden)

^b STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG SURVEILLANCE PROGRAM; EVIDENCE BASED MEDICINE; HEALTH; HUMAN; QUALITY CONTROL;

ADVERSE DRUG REACTION REPORTING SYSTEMS; BENCHMARKING; EVIDENCE-BASED MEDICINE; GLOBAL HEALTH; HUMANS; PHARMACOVIGILANCE;

EID: 84926426303     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-014-0198-z     Document Type: Editorial

References (22)

1. Bate A, Evans SJW. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6):427–36.
2. Norén GN, Hopstadius J, Bate A, Star K, Edwards IR. Temporal pattern discovery in longitudinal electronic patient records. Data Min Knowl Discov. 2010;20(3):361–87.
3. White RW, Tatonetti NP, Shah NH, Altman RB, Horvitz E. Web-scale pharmacovigilance: listening to signals from the crowd. J Am Med Inform Assoc. 2013;20(3):404–8.
4. Freifeld CC, Brownstein JS, Menone CM, et al. Digital drug safety surveillance: monitoring pharmaceutical products in Twitter. Drug Saf. 2014;37(5):343–50.
5. Caster O, Norén GN, Madigan D, Bate A. Large-scale regression-based pattern discovery: the example of screening the WHO global drug safety database. Stat Anal Data Min. 2010;3(4):197–208.
6. Harpaz R, DuMouchel W, LePendu P, Bauer-Mehren A, Ryan P, Shah NH. Performance of pharmacovigilance signal-detection algorithms for the FDA Adverse Event Reporting System. Clin Pharmacol Ther. 2013;93(6):539–46.
7. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009;20(4):512–22 510.1097/EDE.1090b1013e3181a1663 cc.
8. Tatonetti NP, Ye PP, Daneshjou R, Altman RB. Data-driven prediction of drug effects and interactions. Sci Transl Med. 2012;4(125):125–31.
9. Farrington CP, Nash J, Miller E. Case series analysis of adverse reactions to vaccines: a comparative evaluation. Am J Epidemiol. 1996;143(11):1165–73.
10. Ryan P, Schuemie M, Welebob E, Duke J, Valentine S, Hartzema A. Defining a reference set to support methodological research in drug safety. Drug Saf. 2013;36(1):33–47.
11. Coloma P, Avillach P, Salvo F, et al. A reference standard for evaluation of methods for drug safety signal detection using electronic healthcare record databases. Drug Saf. 2013;36(1):13–23.
12. Medical Products Agency (Läkemedelsverket). Läkemedelsverket utreder rapporter om narkolepsi efter vaccination med Pandemrix. 2010. http://www.lakemedelsverket.se/Alla-nyheter/NYHETER-2010/Lakemedelsverket-utreder-rapporter-om-narkolepsi-efter-vaccination-med-Pandemrix/. Accessed 11 Jun 2014.
13. Norén GN, Hopstadius J, Bate A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res. 2013;22(1):57–69.
14. Alvarez Y, Hidalgo A, Maignen F, Slattery J. Validation of statistical signal detection procedures in Eudravigilance post-authorization data: a retrospective evaluation of the potential for earlier signalling. Drug Saf. 2010;33(6):475–87.
15. Caster O, Norén GN, Madigan D, Bate A. Logistic regression in signal detection: another piece added to the puzzle. Clin Pharmacol Ther. 2013;94(3):312.
16. Hallas J. Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiology. 1996;7:478–84.
17. Norén GN, Bergvall T, Ryan PB, Juhlin K, Schuemie MJ, Madigan D. Empirical performance of the calibrated self-controlled cohort analysis within temporal pattern discovery: lessons for developing a risk identification and analysis system. Drug Saf. 2013;36(1):107–21.
18. Bailey S, Singh A, Azadian R, Huber P, Blum M. Prospective data mining of six products in the US FDA adverse event reporting system. Drug Saf. 2010;33(2):139–146.
19. Hauben M, Norén GN. A decade of data mining and still counting. Drug Saf. 2010;33(7):527–34.
20. Lindquist M, Stahl M, Bate A, Edwards IR, Meyboom RH. A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database. Drug Saf. 2000;23(6):533–42.
21. Strandell J, Caster O, Hopstadius J, Edwards IR, Norén GN. The development and evaluation of triage algorithms for early discovery of adverse drug interactions. Drug Saf. 2013;36(5):371–88.
22. Boyce RD, Ryan PB, Norén GN, et al. Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest. Drug Saf. doi:10.1007/s40264-014-0189-0.